Mologen: Preparing for market launch

Starting in  May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologen’s DNA cancer therapy lefitolimod for market launch.

ADVERTISEMENT

Baumann will become a member of the Executive Board and will be responsible for research, preclinical and clinical development, approval and Mologen’s clinical strategy. Until his switch to Mologen, Baumann will continue working as CMO for the biotech German company Noxxon Pharma AG. Prior to joining Noxxon in February 2011, Baumann was Chief Scientific Officer of Focus Clinical Drug Development GmbH and previously active in various research and development positions at Roche and Boehringer Mannheim.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!